Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir

Abstract

SVR was much lower in a real-life patient cohort than in clinical trials (53 % for TVR and 40 % for BOC, compared to 66-75 % in clinical trials).

Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study

“…The mechanisms that determine a lower likelihood of cure are poorly understood. However, these factors likely include impaired immune response in patients with cirrhosis and lower responsiveness to the proposed treatment, limited distribution of drugs in the compromised liver parenchyma, and factors associated with drug toxicity in this group of patients 27. Our results corroborate this hypothesis, as we observed an SVR rate of 46.9% in patients with cirrhosis and 70.6% in patients without cirrhosis.…”

“…The presence of liver cirrhosis has often been associated with a lower likelihood of SVR in the treatment of chronic hepatitis C, regardless of the treatment used 23-26. The mechanisms that determine a lower likelihood of cure are poorly understood.…”

After a Workshop on the Novel Antivirals for Treatment of Hepatitis C Virus Infection (4-6 December 2015, İstanbul)

“…Tedavide birincil amaç, kür ya da şifa olarak da ifade edilen kalıcı virolojik yanıta (KVY) ulaşmak ve HCV infeksiyonuna bağlı mortalite ve morbiditeyi önlemektir. KVY elde edilen hastaların %99'undan fazlası, HCV infeksiyonundan tamamen kurtulmaktadır (1,2).…”

“…DEA ilaçların primer hedefi, yapısal olmayan proteinlerden HCV replikaz kompleksini sentezleten gen gruplarıdır (2)(3)(4)(5). DEA'lar NS3/4A, NS5A ve NS5B gen bölge-lerinden birini inhibe ederek etkili olur (4-7).…”

Efetividade e segurança da terapia tripla com boceprevir ou telaprevir no tratamento da hepatite C crônica genótipo 1 em pacientes atendidos em centros de referência no Brasil

“…Por todas essas características, essa nova geração de DAAs constitui atualmente a terapia de eleição no tratamento da hepatite C crônica em todo o mundo 42,79 . , e a proporção de pacientes cirróticos incluídos foi de 16% a 100% [126][127][128][129][130][131][132][133][134][135][136][137] , superior àquela dos estudos de fase 3 (6% a 27%) [112][113][114][115] . Buscando contribuir em relação a esse tema é que propusemos apresentar a experiência brasileira com o uso da terapia tripla com BOC e TVR por meio de um estudo multicêntrico, no contexto de vida real.…”